NEW YORK, May 17, 2013 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC announces that a class action law suit was filed in the United States District Court for the Northern District of California on behalf of purchasers of Amyris, Inc. ("Amyris" or the "Company") (NasdaqGS: AMRS) stock between April 29, 2011 and February 8, 2012 inclusive (the "Class Period"). The complaint charges Amyris, Inc. and certain of its officers and directors with violation of federal securities laws. On November 1, 2011, Amyris disclosed that it would not be able to produce Biofene in the quantities previously represented but that it had identified and learned to address issues that would allow it to raise the volumes. In reaction to the news, Amyris' share price dropped over 20% from $19.36 per share to $15.47 per share. On February 9, 2012, Amyris executives reported a further slowdown in Biofene production and announced the need to raise funds. Amyris shares dropped an additional 28%, from $9.73 per share to $6.99 per share. No Class has yet been certified in the above action. If you wish to review a copy of the Complaint, to discuss this action, or have any questions, please contact either Peretz Bronstein, Esq. or his investor relations coordinator Eitan Kimelman of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email email@example.com. Those who inquire by e-mail are encouraged to include their mailing address and telephone number. July 15, 2013 is the deadline for investors to seek a lead plaintiff appointment. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.